Epidermal Growth Factor Receptor Mutation-Positive
Non-Small-Cell Lung Cancer in the Real-World Setting in Central
Europe The INSIGHT Study

J 2015

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study

RAMLAU, Rodryg; Tanja CUFER; Peter BERZINEC; Rafal DZIADZIUSZKO; Wlodzimier OSLZEWSKI et al.

Základní údaje

Originální název

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study

Autoři

RAMLAU, Rodryg; Tanja CUFER; Peter BERZINEC; Rafal DZIADZIUSZKO; Wlodzimier OSLZEWSKI; Helmut POPPER; Paolo BAJCIC; Ladislav DUŠEK; Zuzana ZBOŽÍNKOVÁ a Robert PIRKER

Vydání

Journal of Thoracic Oncology, Philadelphia, Lippincott Williams & Wilkins, 2015, 1556-0864

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.040

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083972

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1097/JTO.0000000000000621

UT WoS

000360365400018

EID Scopus

2-s2.0-84940102859

Klíčová slova anglicky

Targeted therapy; INSIGHT; EGFR mutations; Molecular analysis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 9. 2015 15:37, Soňa Böhmová

Anotace

V originále

The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.

Citovat

RAMLAU, Rodryg; Tanja CUFER; Peter BERZINEC; Rafal DZIADZIUSZKO; Wlodzimier OSLZEWSKI; Helmut POPPER; Paolo BAJCIC; Ladislav DUŠEK; Zuzana ZBOŽÍNKOVÁ a Robert PIRKER. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study. Journal of Thoracic Oncology. Philadelphia: Lippincott Williams & Wilkins, 2015, roč. 10, č. 9, s. 1370-1374. ISSN 1556-0864. Dostupné z: https://doi.org/10.1097/JTO.0000000000000621.

@article{1312075,
   author = {Ramlau, Rodryg and Cufer, Tanja and Berzinec, Peter and Dziadziuszko, Rafal and Oslzewski, Wlodzimier and Popper, Helmut and Bajcic, Paolo and Dušek, Ladislav and Zbožínková, Zuzana and Pirker, Robert},
   article_location = {Philadelphia},
   article_number = {9},
   doi = {https://doi.org/10.1097/JTO.0000000000000621},
   keywords = {Targeted therapy; INSIGHT; EGFR mutations; Molecular analysis},
   language = {eng},
   issn = {1556-0864},
   journal = {Journal of Thoracic Oncology},
   title = {Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study},
   volume = {10},
   year = {2015}
}

TY  - JOUR
ID  - 1312075
AU  - Ramlau, Rodryg - Cufer, Tanja - Berzinec, Peter - Dziadziuszko, Rafal - Oslzewski, Wlodzimier - Popper, Helmut - Bajcic, Paolo - Dušek, Ladislav - Zbožínková, Zuzana - Pirker, Robert
PY  - 2015
TI  - Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study
JF  - Journal of Thoracic Oncology
VL  - 10
IS  - 9
SP  - 1370-1374
EP  - 1370-1374
PB  - Lippincott Williams & Wilkins
SN  - 15560864
KW  - Targeted therapy
KW  - INSIGHT
KW  - EGFR mutations
KW  - Molecular analysis
N2  - The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.
ER  -

RAMLAU, Rodryg; Tanja CUFER; Peter BERZINEC; Rafal DZIADZIUSZKO; Wlodzimier OSLZEWSKI; Helmut POPPER; Paolo BAJCIC; Ladislav DUŠEK; Zuzana ZBOŽÍNKOVÁ a Robert PIRKER. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study. \textit{Journal of Thoracic Oncology}. Philadelphia: Lippincott Williams \&{} Wilkins, 2015, roč.~10, č.~9, s.~1370-1374. ISSN~1556-0864. Dostupné z: https://doi.org/10.1097/JTO.0000000000000621.

Přehled o publikaci